Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32044| Title: | Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. | Austin Authors: | Walpole, Imogen;Lee, Belinda;Shapiro, Jeremy;Thomson, Benjamin;Lipton, Lara;Ananda, Sumitra;Usatoff, Val;Mclachlan, Sue-Ann;Knowles, Brett;Fox, Adrian;Wong, Rachel;Cooray, Prasad;Burge, Matthew;Clarke, Kate;Pattison, Sharon;Nikfarjam, Mehrdad ;Tebbutt, Niall C ;Harris, Marion;Nagrial, Adnan;Zielinski, Rob;Chee, Cheng Ean;Gibbs, Peter | Affiliation: | Department of Medical Oncology, Northern Hospital, Victoria, Australia. Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia. Department of Medical Oncology, Cabrini Health, Malvern, Victoria, Australia. Department of Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia. Faculty of Medicine & Health Sciences, Faculty fo Medicine University of Melbourne, Victoria, Australia. Department of Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia. Department of Medical Oncology, St Vincent's Hospital, Victoria, Australia. Walter and Eliza Hall Institute, Melbourne, Victoria, Australia. Department of Medical Oncology, Knox Private Hospital, Victoria, Australia. Department of Medical Oncology, Royal Brisbane Hospital, Queensland, Australia. Department of Medical Oncology, Wellington Hospital, Wellington, New Zealand. Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. Faculty of Medicine & Health Sciences, Faculty fo Medicine University of Melbourne, Victoria, Australia. Medical Oncology Department of Medical Oncology, Monash Medical Centre, Victoria, Australia. Department of Medical Oncology, Westmead Hospital, New South Wales, Australia. Department of Medical Oncology, Orange Hospital, New South Wales, Australia. Department of Medical Oncology, National University Cancer Institute, Singapore. Walter and Eliza Hall Institute, Melbourne, Victoria, Australia. |
Issue Date: | Feb-2023 | metadata.dc.date: | 2022 | Publication information: | Asia-Pacific Journal of Clinical Oncology 2023; 19(1) | Abstract: | Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable METHOD: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and March 2019 within the Australasian Pancreatic Cancer Registry (PURPLE, Pancreatic cancer: Understanding Routine Practice and Lifting End results) was performed. Clinicopathological characteristics, treatment, and outcome were analyzed. Overall survival (OS) comparison was performed using log-rank model and Kaplan-Meier analysis. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32044 | DOI: | 10.1111/ajco.13807 | ORCID: | Journal: | Asia-Pacific Journal of Clinical Oncology | Start page: | 214 | End page: | 225 | PubMed URL: | 35831999 | ISSN: | 1743-7563 | Type: | Journal Article | Subjects: | drug therapy general surgery mortality neoadjuvant therapy pancreatic neoplasms Pancreatic Neoplasms/drug therapy Pancreatic Neoplasms/surgery Pancreatic Neoplasms/pathology Neoadjuvant Therapy/methods Antineoplastic Combined Chemotherapy Protocols/adverse effects Carcinoma, Pancreatic Ductal/drug therapy Carcinoma, Pancreatic Ductal/surgery Carcinoma, Pancreatic Ductal/pathology |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.